Affimed joins the Molecular Imaging Technology Initiative
BMBF awards Affimed a funding grant of €550K
Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the molecular imaging Technology Initiative launched by the German Federal Ministry of education and Research (“BMBF”). Affimed will receive a funded grant totaling more than €550.000 to carry out its part of the project.
BMBF supports the Molecular Imaging Technology Initiative for the development of new diagnostic methods and imaging technologies for clinical use and pharmaceutical applications.
Within this collaboration, Affimed will identify and isolate new molecules binding to membrane-associated targets on tumour tissues, using its highly diverse human antibody libraries. The optimised binding molecules in their final format will be further characterized in vitro by the other above mentioned collaboration partners. The main goal is to find new diagnostic tracer molecules for use in imaging technologies, but identified molecules could also be used for in vitro diagnostic purposes or the development of new pharmaceutical therapeutics.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research

Revolutionary Breakthrough: A Drug Slows Down Leukaemia Progression by Blocking Cancer-Causing Genes - Scientists demonstrate the therapeutic value of a compound that inhibits oncogene translation

In slow motion against antibiotic resistance - How novel therapeutics provide insight into bacteria membranes

How the Brain Reacts to Sleep Deprivation

Texas A&M research aims to improve Lyme disease diagnostics - Scientists are testing Raman spectroscopy as a diagnostic tool for Lyme disease
BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401)
Roche and the Department of Health of Junta de Andalucía Collaborate in Spanish Medical Genome Project

Seeing memories being made
Glycotope received regulatory approval for glycooptimized and fully human glycosylated antibody CetuGEX
